| Literature DB >> 25014997 |
Chinatsu Kawada, Takushi Yoshida, Hideto Yoshida, Ryosuke Matsuoka1, Wakako Sakamoto, Wataru Odanaka, Toshihide Sato, Takeshi Yamasaki, Tomoyuki Kanemitsu, Yasunobu Masuda, Osamu Urushibata.
Abstract
Hyaluronan (HA) is present in many tissues of the body and is essential to maintain moistness in the skin tissues, which contain approximately half the body's HA mass. Due to its viscosity and moisturizing effect, HA is widely distributed as a medicine, cosmetic, food, and, recently marketed in Japan as a popular dietary supplement to promote skin moisture. In a randomized, double-blind, placebo-controlled clinical study it was found that ingested HA increased skin moisture and improved treatment outcomes for patients with dry skin. HA is also reported to be absorbed by the body distributed, in part, to the skin. Ingested HA contributes to the increased synthesis of HA and promotes cell proliferation in fibroblasts. These effects show that ingestion of HA moisturizes the skin and is expected to improve the quality of life for people who suffer from dry skin. This review examines the moisturizing effects of dry skin by ingested HA and summarizes the series of mechanisms from absorption to pharmacological action.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25014997 PMCID: PMC4110621 DOI: 10.1186/1475-2891-13-70
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Figure 1The structure of hyaluronan.
Summary on the skin improving effects of ingested hyaluronan
| Oral consumption of HA at 240 mg daily for 6 weeks | Randomized, double-blind, placebo-controlled trial | HA (M.W.: 80 K) | 22 patients with dry skin (in Japan) | Improved dry skin on the face and whole body | Kajimoto, O. |
| Significant increase of skin moisture | |||||
| Oral consumption of HA at 120 mg daily for 4 weeks | Randomized, double-blind, placebo-controlled trial | HA (M.W.: 80 K) | 35 patients with dry skin (in Japan) | Significant increase of skin moisture | Sato, T. |
| Oral consumption of HA at 120 mg daily for 6 weeks | Randomized, double-blind, placebo-controlled trial | HA (M.W.: 80 K) | 39 female patients with dry skin (in Japan) | Significant increase of skin moisture | Sato, T. |
| Oral consumption of HA at 120 mg daily for 6 weeks | Randomized, double-blind, placebo-controlled trial | HA (M.W.: 30 K) | 42 female patients with dry skin (in Japan) | Significant increase of skin moisture | Yoshida, T. |
| Oral consumption of HA at 37.52 mg daily for 30 days | Randomized, single-blind, placebo-controlled trial | Mixture containing HA (M.W. of HA: 2,500) | 107 healthy subjects (in China) | Significant increase in skin moisture | Terashita, T. |
| Significant increase in skin pH | |||||
| Oral consumption of HA at 100 mg daily for 12 weeks | Prospective open-label trial | Mixture containing HA(M.W.: unknown) | 26 healthy female subjects (Caucasian, African-American, Hispanic, and others) | Improved aging symptoms on the face | Schwartz, S. R. |
Figure 2Skin moisture content changes by HA (MW: 8 × 10) ingestion or placebo. 39 female subjects were randomly divided into two groups (HA group, n = 19; placebo group, n = 20) to minimize the inter-group differences in skin moisture content, skin elasticity and age. The skin moisture content at the lower part of the left eye was measured using a Corneometer® CM 825 before the control period, before the ingestion, and after 3 and 6 weeks of the ingestion. ■ indicates HA; □ indicates placebo. An unpaired t-test was used to compare the two groups. Data are presented as mean ± S.E. Asterisks indicate a statistically significant difference, *p < 0.05.
Figure 3Skin moisture content is changed by HA (MW: 3 × 10) ingestion or placebo. 42 female subjects were randomly divided into two groups (HA group, n = 20; subjects placebo group, n = 22) to minimize the inter-group differences in skin moisture content and age. The skin moisture content at the cheeks were measured with a Corneometer® CM 825 before the ingestion, after 3 and 6 weeks of the ingestion, and 2 weeks after the end of ingestion. Variations in the skin moisture content relative to baseline level are shown. ■ indicates HA; □ indicates placebo. An unpaired t-test was used to compare the groups. Data are presented as mean ± S.E. Asterisks indicate a statistically significant difference, *p < 0.05.
Figure 4Metabolic pathway of ingested hyaluronan.
Safety tests of hyaluronan
| Daily oral administration test for 8 weeks | HA | Chicken comb | 9 × 105 | Human | No abnormalities in hematology due to 240 mg/kg body weight/day for 12 weeks | Sato, T. |
| Daily oral administration test for 1 year | HA | Chicken comb | 9 × 105 | Human | No abnormalities on clinical observations due to oral administration of 200 mg/kg body weight/day for 1 year | Tashiro, T. |
| Single-dose toxicity test | Sodium hyaluronate | Chicken comb | Not shown | Mouse | LD50 (mg/kg body weight) > 2400 | Nagano, K. |
| LD50 (mg/kg body weight) > 1200 | Nagano, K. | |||||
| Sodium hyaluronate | Chicken comb | Not shown | Rat | LD50 (mg/kg body weight) > 800 | Nagano, K. | |
| LD50 (mg/kg body weight) > 1200 | Nagano, K. | |||||
| Microbial fermentation | 16.8 × 105 | LD50 (mg/kg body weight) > 200 | Morita, H. | |||
| Sodium hyaluronate | Chicken comb | Not shown | Rabbit | LD50 (mg/kg body weight) > 1000 | Nagano, K. | |
| LD50 (mg/kg body weight) > 900 | Nagano, K. | |||||
| Repeated-dose toxicity test | HA | Microbial fermentation | 3 × 105 | rat | No abnormalities on clinical observations due to administration in doses equivalent to 0, 34, 235, 3536 mg/kg body weight/day. | Oe, M. |
| Sodium hyaluronate | Chicken comb | Not shown | NOAEL 48 mg/kg body weight, or more | Ishihara, M. | ||
| Antigenicity test | Sodium hyaluronate | Microbial fermentation | 18.8 × 105 | Bacteria (Ames test) | No mutagenicities to | Sugiyama, C. |
| Not shown | 21.2 × 105 | No mutagenicities to | Onishi, M. | |||
| Chicken comb | 20.0–21.2 × 105 | Mouse, rat, rabbit | No antigenicity on PCA reaction in mice or guinea pigs | Takemoto, M. | ||
| No antigenicity on active systemic anaphylactic reaction in guinea pigs |